| RRC ID |
67416
|
| 著者 |
Yamaguchi A, Usami K, Shimabe M, Hasegawa K, Asada M, Motoki K, Tahara T, Masuda K.
|
| タイトル |
The novel CA IX inhibition antibody chKM4927 shows anti-tumor efficacy in vivo.
|
| ジャーナル |
Anticancer Res
|
| Abstract |
Carbonic anhydrase IX (CA IX) is an attractive target for cancer therapy. Many anti-CA IX antibodies have been reported but few have been shown to possess inhibition activity. Furthermore, effective use of CA IX-inhibition antibodies for cancer immunotherapy has not been well-validated since data are mainly limited to in vitro assays. In this study, we established that chKM4927, an anti-CA IX chimeric antibody, recognizes CA IX and has CA IX-specific inhibition activity. ChKM4927 also retains antibody-dependent cellular cytotoxicity (ADCC) activity against CA IX-expressing cancer cells. Compared to controls, chKM4927 treatment (10 mg/kg) showed anti-tumor activity in the VMRC-RCW xenograft model in vivo. ChKM4927-attenuated ADCC activity showed equally effective anti-tumor activity. These results suggest that the CA IX-inhibition antibody chKM4927 has an anti-tumor effect in the VMRC-RCW xenograft model via an ADCC-independent mechanism.
|
| 巻・号 |
35(4)
|
| ページ |
1997-2004
|
| 公開日 |
2015-4-1
|
| PII |
35/4/1997
|
| PMID |
25862852
|
| MeSH |
Antibodies, Monoclonal / administration & dosage*
Antibody-Dependent Cell Cytotoxicity / immunology
Antigens, Neoplasm / immunology*
Antigens, Neoplasm / therapeutic use
Carbonic Anhydrase IX
Carbonic Anhydrases / immunology*
Carbonic Anhydrases / therapeutic use
Cell Line, Tumor
Enzyme Inhibitors / administration & dosage*
Enzyme Inhibitors / immunology
Humans
Molecular Targeted Therapy
Neoplasms / immunology
Neoplasms / pathology
Neoplasms / therapy*
Xenograft Model Antitumor Assays
|
| IF |
1.994
|
| リソース情報 |
| ヒト・動物細胞 |
OS-RC-2(RCB0735) |
